PURPOSE: Stage III Non-Small Lung Cancer has a poor prognosis. Reports suggest that five year survival after current treatment is between 14 to 24 percent. We reviewed our institutional experience in order to document survival in this difficult patient cohort.
METHODS: We reviewed the medical record and tumor registry follow up data on 100 consecutive patients who underwent pneumonectomy for lung cancer at the University of Kentucky.
RESULTS: We identified thirty-six patients in Stage III who underwent pneumonectomy. Ten patients had surgery only, eight patients received adjuvant chemotherapy, and eighteen patients received neoadjuvant therapy. There was one surgical death in this series. Mean follow-up was 2.9 years. One, three and five year survival was 66%, 38% and 38% respectively(Figure 1). Five year survival for the group with adjuvant therapy was 60%.
CONCLUSIONS: Most lung cancer patients present with advanced disease and the prognosis remains poor. In our hands, resection offers an above average chance of long term survival when supplemented with neoadjuvant and /or adjuvant therapy.
CLINICAL IMPLICATIONS: Multimodality offers the best chance for survival for Stage III non-small cell lung cancer patients.
DISCLOSURE: The following authors have nothing to disclose: Sibu Saha, Rohan Kalathia, Victor Ferraris, Daniel Davenport, Timothy Mullett, Jay Zwischenberger
No Product/Research Disclosure Information